<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>83(12)</volume><submitter>Miller BE</submitter><pubmed_abstract>&lt;h4>Aims&lt;/h4>Cathepsin C (CTSC) is necessary for the activation of several serine proteases including neutrophil elastase (NE), cathepsin G and proteinase 3. GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study.&lt;h4>Methods&lt;/h4>Single escalating oral doses of GSK2793660 from 0.5 to 20 mg or placebo were administered in a randomized crossover design to healthy male subjects; a separate cohort received once daily doses of 12 mg or placebo for 21 days. Data were collected on safety, pharmacokinetics, CTSC enzyme inhibition and blood biomarkers.&lt;h4>Results&lt;/h4>Single, oral doses of GSK2793660 were able to dose-dependently inhibit whole blood CTSC activity. Once daily dosing of 12 mg </pubmed_abstract><journal>British journal of clinical pharmacology</journal><pagination>2813-2820</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5698569</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660).</pubmed_title><pmcid>PMC5698569</pmcid><pubmed_authors>Goyal N</pubmed_authors><pubmed_authors>Mayer RJ</pubmed_authors><pubmed_authors>Lazaar AL</pubmed_authors><pubmed_authors>Heslop T</pubmed_authors><pubmed_authors>Boyce M</pubmed_authors><pubmed_authors>Bal J</pubmed_authors><pubmed_authors>Carpenter D</pubmed_authors><pubmed_authors>Miller BE</pubmed_authors><pubmed_authors>Churchill A</pubmed_authors><pubmed_authors>Dallow N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660).</name><description>&lt;h4>Aims&lt;/h4>Cathepsin C (CTSC) is necessary for the activation of several serine proteases including neutrophil elastase (NE), cathepsin G and proteinase 3. GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study.&lt;h4>Methods&lt;/h4>Single escalating oral doses of GSK2793660 from 0.5 to 20 mg or placebo were administered in a randomized crossover design to healthy male subjects; a separate cohort received once daily doses of 12 mg or placebo for 21 days. Data were collected on safety, pharmacokinetics, CTSC enzyme inhibition and blood biomarkers.&lt;h4>Results&lt;/h4>Single, oral doses of GSK2793660 were able to dose-dependently inhibit whole blood CTSC activity. Once daily dosing of 12 mg </description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Dec</publication><modification>2026-04-29T07:14:15.502Z</modification><creation>2019-03-27T00:09:13Z</creation></dates><accession>S-EPMC5698569</accession><cross_references><pubmed>28800383</pubmed><doi>10.1111/bcp.13398</doi></cross_references></HashMap>